EMA Authorised: Elrexfio (elranatamab) — Pfizer Europe MA EEIG

View source ↗

Summary

The EMA authorised Elrexfio (elranatamab) for multiple myeloma under conditional approval by Pfizer Europe MA EEIG.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ELREXFIO (ELRANATAMAB-BCMM)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Pfizer Europe MA EEIG. Decision date: 13/11/2025. Conditional approval